**Richtlijn prostaat – PICO 5 – Evidence table**

**Uitgangsvraag:**

Uitgangsvraag: Welke behandeling is geïndiceerd voor pijnlijke botmetastasen bij patiënten met een gemetastaseerd castratie-resistent prostaatcarcinoom?”

**Patiëntengroep**: Patiënten met gemetastaseerd castratie-resistent prostaatcarcinoom (mCRPC) en pijnlijke botmetastasen

**Intervention**: Uitwendinge radiotherapie

**Comparison**: Geen behandeling of een (of meer) van de andere behandelingen

**Outcome**: Reductie van pijnklachten, Kwaliteit van leven, Toxiciteit

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **I Study ID** |  **II Method** | **III Patient characteristics** | **IV Intervention(s)** | **V Results**  | **VI Critical appraisal of study quality** |
| * Oosterhof et al, 2003[[1](#_ENREF_1)]
 | * RCT
* Conflict of interest not reported
* Multicenter, multiple countries (NLD, BE, UK, DK)
* Sample size: 203 patients
* Duration: not reported
* No protocol found
 | * Eligibility criteria: Prostate cancer. Progression and/or appropriate anti-androgen treatment, previous hormonal therapy, painful osseous

metastases.* Baseline characteristics:

Median age: 70.7 vs 70.7 years; castration 99/101 vs 100/102. Median duration of hormonal treatment: 20.1 months (2.1-123.5) vs 15.7 months (1-156.9). | * Strontium89 (S) (N = 101).

vs * Radiotherapy (R) (N = 102)
 | **Pain reduction**S: 34.7%R: 33.3% **Quality of Life**Not reported**Adverse events:****Grade 3 or 4 non-haematologic side effect** nausea/vomiting: S-group: 4%R-group: 1%DiarrhoeaS-group: 2%R-group: 8.3%Pain flare: S-group: 18.4%R-group: 8.2%No p-values**Grade 3 or 4 haematologic side effect**S-group: 0%R-group: 2%No p-value  | * Unclear risk of bias, unclear allocation concealment, unclear blinding.
 |

BE Belgium, DK Denmark, NLD Netherlands, R radiotherapy, RCT randomized controlled trial, S Strontium, UK United Kingdom,

**References**

[1] Oosterhof GO, Roberts JT, Reijke TM, Engelholm SA, Horenblas S, Maase H, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *European urology* 2003:519-26.